Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
Subodh VermaJaved ButlerBarry A BorlaugMelanie DaviesDalane W KitzmanSanjiv J ShahMark C PetrieEric BarrosCecilia RönnbäckLene Sommer VestergaardMorten SchouJustin A EzekowitzKavita SharmaShachi PatelKhaja M ChinnakondepalliMikhail N Kosiborodnull nullPublished in: Journal of the American College of Cardiology (2024)
In patients with obesity-related HFpEF, semaglutide 2.4 mg reduced body weight to a greater extent in women, and produced similar improvements in HF-related symptoms, physical limitations, and exercise function, regardless of sex. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511; and Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP HFpEF DM]; NCT04916470).
Keyphrases
- type diabetes
- insulin resistance
- heart failure
- metabolic syndrome
- weight loss
- high fat diet induced
- body weight
- weight gain
- physical activity
- polycystic ovary syndrome
- glycemic control
- adipose tissue
- cardiovascular disease
- left ventricular
- skeletal muscle
- atrial fibrillation
- mental health
- acute heart failure
- body mass index